BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK
8.9450
11-February-25 15:32:01
15 minutes delayed
Stocks
+0.3150
+3.65%
Today's range
8.5400 - 9.0000
ISIN
N/A
Source
NASDAQ
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Oct 2023 07:00:41 By Nasdaq GlobeNewswire
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Sep 2023 07:00:46 By Nasdaq GlobeNewswire
-
BioCryst to Present at Upcoming Investor Conferences
23 Aug 2023 16:01:54 By Nasdaq GlobeNewswire
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2023 16:01:28 By Nasdaq GlobeNewswire
-
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
03 Aug 2023 07:00:58 By Nasdaq GlobeNewswire
-
BioCryst to Report Second Quarter 2023 Financial Results on August 3
20 Jul 2023 07:00:37 By Nasdaq GlobeNewswire
-
BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey
19 Jul 2023 07:00:00 By Nasdaq GlobeNewswire
-
BioCryst to Participate in the 2023 US HAEA National Summit
17 Jul 2023 07:00:00 By Nasdaq GlobeNewswire
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Jul 2023 07:00:12 By Nasdaq GlobeNewswire
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Jun 2023 07:00:42 By Nasdaq GlobeNewswire
-
BioCryst to Present at Upcoming Investor Conference
01 Jun 2023 07:00:45 By Nasdaq GlobeNewswire
-
31 May 2023 07:02:04 By Nasdaq GlobeNewswire
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile
22 May 2023 07:00:00 By Nasdaq GlobeNewswire
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 May 2023 16:01:01 By Nasdaq GlobeNewswire
-
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
03 May 2023 07:00:55 By Nasdaq GlobeNewswire
-
27 Apr 2023 07:00:01 By Nasdaq GlobeNewswire
-
BioCryst to Report First Quarter 2023 Financial Results on May 3
19 Apr 2023 07:00:27 By Nasdaq GlobeNewswire
-
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon
18 Apr 2023 07:00:00 By Nasdaq GlobeNewswire
-
BioCryst to Present at Upcoming Investor Conferences
12 Apr 2023 07:00:00 By Nasdaq GlobeNewswire
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2023 07:00:36 By Nasdaq GlobeNewswire